Research efforts are focused on the comprehensive genomic profiling of CRC, examining mutations in key genes such as KRAS, NRAS, BRAF, MSI, HER2, and PIK3CA to identify new actionable mutations and signaling pathways. This evidence concerns the gene KRAS and colorectal carcinoma.